Senti Biosciences Inc (SNTI) has a current Price-to-Book (P/B) ratio of 3.56. Compared to its 3-year average P/B ratio of 1.14, the current P/B ratio is approximately 212.94% higher. Relative to its 5-year average P/B ratio of 0.39, the current P/B ratio is about 814.76% higher. Senti Biosciences Inc (SNTI) has a Forward Free Cash Flow (FCF) yield of approximately -173.86%. Compared to its 3-year average FCF yield of -250.00%, the current FCF yield is approximately -30.46% lower. Relative to its 5-year average FCF yield of -168.55%, the current FCF yield is about 3.15% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SNTI competitors is 11.98, providing a benchmark for relative valuation. Senti Biosciences Inc Corp (SNTI.O) exhibits a P/S ratio of 57.84, which is 382.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SNTI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SNTI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SNTI currently overvalued or undervalued?

What is Senti Biosciences Inc (SNTI) fair value?

SNTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Senti Biosciences Inc (SNTI) is between 0.18 to 1.19 according to relative valuation method.

How does SNTI's valuation metrics compare to the industry average?

The average P/S ratio for SNTI's competitors is 11.98, providing a benchmark for relative valuation. Senti Biosciences Inc Corp (SNTI) exhibits a P/S ratio of 57.84, which is 382.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Senti Biosciences Inc (SNTI) as of Mar 04 2026?

As of Mar 04 2026, Senti Biosciences Inc (SNTI) has a P/B ratio of 3.56. This indicates that the market values SNTI at 3.56 times its book value.

What is the current FCF Yield for Senti Biosciences Inc (SNTI) as of Mar 04 2026?

As of Mar 04 2026, Senti Biosciences Inc (SNTI) has a FCF Yield of -173.86%. This means that for every dollar of Senti Biosciences Inc's market capitalization, the company generates -173.86 cents in free cash flow.

What is the current Forward P/E ratio for Senti Biosciences Inc (SNTI) as of Mar 04 2026?

As of Mar 04 2026, Senti Biosciences Inc (SNTI) has a Forward P/E ratio of -0.68. This means the market is willing to pay $-0.68 for every dollar of Senti Biosciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Senti Biosciences Inc (SNTI) as of Mar 04 2026?

As of Mar 04 2026, Senti Biosciences Inc (SNTI) has a Forward P/S ratio of 57.84. This means the market is valuing SNTI at $57.84 for every dollar of expected revenue over the next 12 months.

SNTI Valuation